Back to results
US 6,294,165 B1Granted
Defective packaging non-oncoviral vectors based on HIV
AssigneeSyngenix Limited
InventorsAndrew Michael Lindsay Lever, Eric Hunter
Life of this patent
Estimating the term…
Abstract
Novel vectors are capable of producing MPMV (Mason-Pfizer Monkey Virus) proteins but not of packaging MPMV RNA, and the information about the packaging signal in MPMV and HIV can be used to create MPMV and HIV vectors that are capable of transferring foreign genes, e.g. for use in gene therapy.
Claims6
A replication defective HIV-based vector comprising packaging nucleotides, wherein the packaging nucleotides comprise an HIV 5′ leader sequence and the cis-acting REV responsive element of HIV;
- a heterologous gene;
- and, flanking the packaging nucleotides and the heterologous gene, HIV sequences for packaging, reverse transcription and integration of the vector into target cells and expression of the heterologous gene.
Dependencies are inferred from the claim text.